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Questionnaires were circulated to UK patients and health care professionals (HCPs) participating in the Taxotere as Adjuvant
ChemoTherapy (TACT) trial in autumn 2004 asking if and how trial results, when available, should be conveyed to patients. A total of
1431 (37% of surviving UK TACT patients) returned questionnaires. In all, 30 (2%) patients did not want results. In all, 554 (40%)
patients preferred to receive them via their hospital; 664 (47%) preferred results posted directly to their home, 177 (13%) preferred
a letter providing a telephone number to request results. Six hundred and twelve patients thought results should come directly
from the trials office. One hundred and seventy-six HCPs from 89 UK centres (86%) returned questionnaires. In all, 169 out of 176
patients (96%) thought results should be written in lay terms for patients. Seventy (41%) preferred patients to receive results via their
hospital; 64 (38%) preferred a letter providing a telephone number to request results, and 32 (19%) preferred results posted directly
to patients. Thirty-one HCPs (18%) thought results to patients should come directly from the trials office. A total of 868 (61%)
patients thought next of kin of deceased patients should receive results, 543 (38%) did not; 47 (27%) HCPs thought they should; 118
(68%) did not.
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The view that researchers have an obligation (Fernandez et al,
2003) to provide results of clinical trials to those who participate
in them has reached mainstream thinking, with professional
medical bodies (Royal College of Physicians, 1990) supporting this
approach. However, within the UK, recently updated national
guidelines on information sheets for trial participants (www.nres.
npsa.nhs.uk) advise caution in disseminating results to partici-
pants, an approach which is justified by the mixed findings
from several studies (Snowdon et al, 1998; Richards et al, 2003;
Dixon-Woods et al, 2006). The guidelines’ distinction between
‘broad scientific results of a trial’ and ‘results of relevance to the
individual’ is welcomed, as the broad scientific results may need
to be presented to participants in the context of (possibly)
differing results from similar trials, which taken individually may
be confusing or inconclusive, and normally have no bearing on the
patients’ future clinical care.
For cancer treatment trials in patients with early disease, a lapse
of several years from trial entry to availability of results means that
unexpected contact to convey results could cause undue alarm.
Two further studies (Partridge et al, 2004, 2005) both show that
the majority of cancer patients would like to receive results, but
provide conflicting data on whether patients want results conveyed
by their doctor or they are comfortable receiving them by post. For
trials with survival as an endpoint, the issue of how, when and
whether to disseminate results to the next of kin of those who have
died has not been fully explored.
In this paper, we report an attempt to evaluate whether patients
who took part in the Taxotere as Adjuvant ChemoTherapy (TACT)
trial (Barrett-Lee et al, 2002) wish to be informed of the trial results
when they become known. We sought preferences relating to the
possible practical mechanisms for distributing them to participat-
ing patients, and in the case where the patient has subsequently
died, the extent to which participants supported the idea that their
next of kin should receive the results. We compared the views of
participating patients with those of the health care professionals
involved with the TACT trial, that is those most likely to convey
trial results to patients, who will appreciate the scientific context,
and practical considerations which may not be obvious to patients.
Taxotere as Adjuvant ChemoTherapy is a large multicentre
trial in patients with early breast cancer, which recruited 4124
women from 103 participating UK hospitals, and 38 from 1 Belgian
centre between January 2001 and June 2003, and compares
an anthracycline–taxane chemotherapy sequence with standard
UK anthracycline chemotherapy. Treatment was scheduled to last
approximately 6 months. Long term follow-up will allow compa-
rison of the rates of disease relapse and death between treatment
groups. A survey of the UK patients was conducted in the autumn
of 2004, well before clinical outcome data was known. Median time
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ssince randomisation was 28 months (range¼15–44 months),
and 282 (7%) had died. The timing aimed to capture patients’
views after treatment was completed and normal day to day
activities were resumed, at a time when the rate of disease relapse
and death remained low and ahead of the attainment of the
trial’s results.
AIM
We aimed to find out from trial patients whether they wanted to
receive trial results written in lay terms when they are available,
and how they considered they wanted to receive them. We
compare their preferences with those expressed by health care
professionals (oncologists and nurses) who had participated in the
TACT trial.
METHOD
Following ethics approval from the South East Multi-Centre
Research Ethic Committee, a patient newsletter accompanied by
a patient questionnaire was sent to UK hospitals to distribute to
surviving TACT patients. The newsletter aimed to remind patients
that follow-up continued, and explained why the trial had so
far not produced any published results. Health Care Professionals
(HCPs) either posted these directly to trial patients, or distributed
them in the hospital clinic. Health care professionals could
withhold the newsletter and questionnaire from individuals
or groups of patients if they considered them inappropriate for
example, those receiving palliative care. The exact number of
questionnaires distributed is not known, however feedback
from hospitals following an earlier patient newsletter suggests
approximately 3000 of a possible 3842 were distributed.
Explanation of advantages and disadvantages of 3 methods of distributing results 
Results posted as soon as they are available 
Advantages: Get results quickly. 
Patients could be distressed by sudden intrusion, especially if results are different from what
Disadvantages: Results arrive unexpectedly.  
they expected. 
confidential information and address lists quickly become out of date).
confidential information and address lists quickly become out of date).
Patient's doctor or nurse not on hand to answer questions. 
If researchers post the results to patients' home addresses (Hospitals need to disclose this 
Letter saying results are available, with a phone number to call for a copy 
Advantages: Patients can choose timing of when to get results. 
Patients are expecting results to arrive. 
Disadvantages: Need to make a phone call to an information helpline. 
Patient's doctor or nurse not on hand to answer questions. 
If researchers post the letter to patients' home addresses (Hospitals need to disclose this. 
Results given at a hospital visit 
Advantages: Doctor or nurse on hand to explain results and answer questions straight away. 
Disadvantages: Could be a delay in getting results.
If the results affect individual patient's care, this can be discussed straight away.
Questionnaire:
Please tick one box below to show which of the four options you, personally, would like:   
1. I prefer results to be posted to me as soon as they are available 
2. I prefer a letter telling me when results are available, with a phone number to call for a copy 
3. I prefer my hospital doctor or nurse to tell me the results at a clinic visit 
4. I do not want to know the results 
If you have ticked option 1 or 2, please choose one of the following two options by ticking one box
My home address should be made available to the Institute of Cancer Research so they can post 
results to me directly 
My home address is confidential and the Institute of Cancer Research should send results to my 
hospital, for the hospital to post them to me 
Unfortunately some patients will have died before the results become available.  Do you think the next of 
kin of such patients should be told of the results? 
Yes No
please answer the question below 
If the patient previously decided they did not want the results, should their next of kin receive them? 
Yes No
What is your age group? Please tick one box 18 - 39 40 - 59 60 - 69 70 or over
What county do you live in? (e.g. Yorkshire)
Would you like to complete questionnaires in the future about patients' attitudes and preferences? 
Yes, any time Yes, but no more than one No
Figure 1 Patient questionnaire.
How do patients want to learn of results of clinical trials?
L Johnson et al
35
British Journal of Cancer (2008) 98(1), 34–38 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThe questionnaire described three methods of distributing
results, and explained the advantages and disadvantages of each,
as perceived by the researchers at the Clinical Trials & Statistics
Unit at the Institute of Cancer Research (ICR-CTSU). Patients were
then asked if they wanted results written in lay terms, and if so,
which of the three methods they preferred (Figure 1). Patients were
also asked about the theoretical scenario of whether and how
to convey results to the next of kin of patients who had died.
Information on patient age group and geographical region was
collected to allow any age or regional trends to be identified. A
similar survey of participating HCPs conducted simultaneously
asked whether and how results should be distributed to patients,
and offered the same three options. (Figure 2). Additional advant-
ages and disadvantages, which were of no relevance to patients,
were included for HCPs, which highlighted the impact of the
different distribution methods on working practices. All respon-
dents who preferred patients to receive results by post were also
asked if, in principal, they thought ICR-CTSU as the coordinating
The following (additional) advantages and disadvantages were presented to HCPs: 
Results posted as soon as they are available 
Disadvantages: Clinicians and nurses could be deluged with patients’ questions 
Letter saying results are available, with a phone number to call for a copy 
Advantages: Results only go to patients who want them, and at a time of their choosing (altered 
wording only) 
Disadvantages:  Clinicians and nurses do not know which patients have received results and when, and 
may not be available to answer questions 
Clinicians and nurses could be deluged with patients’ questions 
Results given at a hospital visit 
Disadvantages: Resources may not be available for extra appointments to explain results  
Many patients could be followed up at other hospitals or GPs, and may not get the 
results for many months, if at all 
Logistically difficult to monitor and/ or recall patients
Questionnaire:
Should the TACT trial results be given to patients: 
Unfortunately some patients will have died before the results become available.  Do you think the next of 
kin of such patients should be told of the results? 
No Yes If the patient previously decided they did not want the results, should  
their next of kin still have the opportunity to receive them? 
No Yes
Should ICR-CTSU send: 
the results directly to the patients 
home address*
or
a letter to the patients home 
address saying, results are 
available, with a central national 
helpline phone number to 
request them if they wish*
* The Institute of Cancer Research does 
not normally collect patients' addresses, 
and does not have the home addresses of 
TACT trial patients.
Should ICR-CTSU send:
results for hospitals to forward on to patients’ home addresses 
or
a letter for hospitals to forward on to patients’ home addresses 
saying the results are available, with a central national helpline 
phone number to request them if they wish 
or should they be: 
given to patients by the clinician or nurse at their next hospital 
visit 
or should: 
patients be recalled for an appointment to discuss the results 
with the clinician or nurse 
Should trial results be written in lay terms and given to participating patients?  Yes  No
By ICR-CTSU *  By the patients’ hospital 
Figure 2 Health Care Professional Questionnaire.
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strials office, should in future hold addresses so they could send
results directly to patients’ homes. HCPs were encouraged to
circulate the questionnaire to all appropriate staff directly involved
in the TACT trial, therefore the precise number distributed is
not known.
RESULTS
Providing results to patients
Patients’ views In all, 37% (1431) of the UK TACT trial
population who remained alive at the time the questionnaire
was distributed completed and returned it (Table 1). Of those
who responded, 30 (2%) patients stated that they did not want trial
results, and 6 (o1%) did not answer this question (Table 2).
A total of 612 patients (44% of the 1395 who wanted results)
thought that for future trials, communication of results to patients
should come directly from ICR-CTSU. There was no significant
difference in age distribution (P¼0.35) nor in current country of
residence (P¼0.5) between those who would like to have the trial
results and those who do not (data not shown). No association
was found between preferred method of delivery and age group
(P¼0.34), nor between preferred method of delivery and UK
country of residence (P¼0.55). The distribution between age
groups and UK country is shown in Table 1.
Health care professionals’ views In all 176 HCPs responses
came from 89 (86%) participating UK centres, of which 93
(53%) were nurses, 80 (45%) clinicians, and three (2%) did not
specify (Table 2). Among HCPs there was a clear preference for
communicating the results in the clinic (41%), with no difference
between clinicians and nurses (P¼0.18). as to which of the three
methods of communicating results they preferred; however, the
difference in response between HCPs and patients is significant
(Po0.001).
Despite knowing that patient addresses are not held by
ICR-CTSU, 28 (16%) thought that communication of results to
patients should come directly from ICR-CTSU (Table 2).
Providing results to next of kin of deceased patients
A total of 61% (868) patients thought that the next of kin of
patients who had died should receive trial results, compared with
only 27% (47) HCPs. However, of those who held this view, the
proportion who also thought the results should be conveyed to the
next of kin of patients who had not wanted the results was very
similar for patients and HCPs (60 and 57% respectively) (Figure 3).
DISCUSSION
Although the response rate of 37% was higher than anticipated, we
cannot assume the results are representative of the views of 2411
patients who were not given the questionnaire or chose not to
return it. For those who did not reply, we do not know how many
did not want results, or did not feel strongly enough to complete
and return it. That 30 patients (2% of respondents) felt strongly
enough about not receiving the results to return the completed
questionnaire highlights the need to ask patients if they want
results prior to them being distributed.
Unlike trials testing ongoing treatment for a chronic disease,
results of most trials of adjuvant cancer treatment have no impact
on future care of participants, nor do they provide information
about the future implications of trial treatment for individuals. It
is commonplace within adjuvant cancer trials for the collection
of long-term follow-up data to continue and the dissemination
of trial results to patients could (hypothetically) introduce bias
and jeopardise future knowledge and long term outcome data,
Table 1 Distribution of age groups and UK country of patients
responding to questionnaires
UK country
Number (%)
of patients
Age
group
Number (%)
of patients
England 1140 (80) 18–39 106 (7)
Scotland 102 (7) 40–59 1090 (76)
Wales 92 (6) 60–69 217 (15)
N Ireland 28 (2) 70+ 15 (1)
Not specified 69 (5) 3 (o1)
Total 1431 (100) 1431 (100)
Table 2 Patient and HCP preferences for distributing results to patients
Patients (%) HCPs (%)
Trial results (n¼1431) (n¼176)
Want results in lay terms (for patients) 1395 (97) 169 (96)
Do not want (patients to receive) results 30 (2) 5 (3)
Did not answer 6 (o1) 2 (1)
Patients (%) HCPs (%)
Method of distribution preferred (n¼1395) (n¼169)
Posted to patients when available 664 (47) 32 (19)
By patient’s hospital 140 (21) 20 (62)
By ICR-CTSU 521 (79) 12 (38)
Did not answer 3 (o1) —
Letter to say results are available, with national
helpline number to request a copy
177 (13) 64 (38)
By patient’s hospital 86 (49) 48 (75)
By ICR-CTSU 91 (51) 16 (25)
Results given to patients by clinician or nurse 554 (40) 70 (41)
At next hospital visit — 65 (93)
Patients recalled for appointment to discuss
results
— 5 (7)
Did not express any preference — 3 (2)
Both patients and Health Care Professionals (HCPs) were asked: 
Do you think the next of 
kin of such patients 
should be told of the 
results?
Patients 
HCPs 
868, 61% 543, 38%
519, 36%
309, 22%
40, 3%
20, 1%
118, 68% 47, 27%
27, 15%
16, 9%
4, 2%
11, 6%
Yes No Did not answer
If the patient previously 
decided they did not want the 
results, should their next of 
kin receive them?
Figure 3 Distributing results to next of kin of deceased patients.
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sparticularly long-term data on quality of life. This risk, however
small, needs to be balanced against the knowledge that the broad
scientific trial results will only provide information about an
average treatment effect of the experimental vs control treatment
in one single trial, which should be viewed in the context of the
worldwide evidence.
It is difficult for trial participants to foresee how they will react
to receiving the results. For example, in a trial showing a small
difference between two treatment arms, approximately 50% of
patients will have received treatment, which was, on average,
‘inferior’. However, it may not be inferior for most patients who
received it. In addition, highlighting the importance of clear
patient information at trial entry about the uncertainty of treat-
ment superiority, raises the question of how to explain to patients
that ‘inferior’ in the trial does not necessarily mean ‘inferior’ for
them, personally.
A single trial is unlikely to provide a definitive answer to the
original research question; for patients in the TACT trial an
unbiased account of the results would require researchers to
explain them within the context of a systematic overview of the
emerging worldwide data on taxanes. Added to that are the uncert-
ainties of confidence intervals and the caveat that any promising
subgroup analyses are hypothesis generating, not results in
themselves. Thus trial results written in lay terms will not only
fail to provide the personalised interpretation that patients may
want, but if delivered without due consideration to the timing
of any relapse a patient may have experienced, or without
consideration of the method of distribution, there is a risk they
could unnecessary heighten concerns about long-term prognosis
and future clinical care.
To avoid unnecessary distress, information that accompanied
this survey did not explain that results depended on enough
patients relapsing or dying, yet it is this that allows statistically
reliable and precise comparisons between treatment groups.
Without this knowledge, can patients know whether they would
want the results if they had relapsed? Patient response to receiving
results could be further complicated by knowing they had also
received the ‘inferior’ treatment. The timing of this questionnaire
was such that very few patients had relapsed. If those few patients
were excluded from receiving the questionnaire, the views of
patients who have relapsed may be under-represented.
Patients were very divided on whether the next of kin of
deceased patients should be given trial results, and HCPs erred
towards thinking next of kin should not receive results. Qualifying
comments made on questionnaires suggest this was a difficult
ethical question.
The majority of patients opting to receive results by post
expressed a preference for ICR-CTSU to collect patients’ addresses
for future trials, bypassing the hospital to convey results to
patients as soon as they are available; an option that suggests a
higher priority for speed than confidentiality of personal data. The
responses from HCPs suggest an expectation that trial results need
to be interpreted for individual patients. The lower priority given
to alacrity could also suggest an awareness that peer-reviewed
journals do not allow widespread dissemination of results prior to
publication. In addition, results of high profile trials often fall
under the media spotlight ahead of any adequate peer review.
Dissemination of results by the media and the ‘spin’ put on them
in the popular press may be misinterpreted by trial participants,
with HCPs left to interpret results in a way that seems to patients to
be less attractive.
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